Restricted accessResearch articleFirst published online 2012-12
Susceptibility to Etravirine of HIV Type 1 Subtype C Isolates from Nevirapine/Efavirenz-Experienced Patients: Comparative Interpretation of ANRS and STANFORD Algorithms
We analyzed subtype C HIV-1 isolates from patients at failure of a regimen including nevirapine or efavirenz for their susceptibility or resistance to etravirine according to the ANRS and STANFORD algorithms. Statistical analysis showed a consensus that more than 45% of these viral strains are potentially resistant to etravirine.
Get full access to this article
View all access options for this article.
References
1.
VingerhoetsJ, TambuyzerL, AzijnHet al.Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS, 2010; 24:503–514.
2.
MarcelinAG, FlandreP, DescampsDet al.Factors associated with virological response to etravirine in non-nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother, 2010; 54:72–77.
3.
DeshpandeA, Recordon-PinsonP, DeshmukhRet al.Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses, 2004; 20:1032–1035.
4.
MaigaAI, DescampsD, Morand-JoubertLet al.Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother, 2010; 54:728–733.
5.
BennettDE, CamachoRJ, OteleaDet al.Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One, 2009; 4:e4724.
6.
NeogiU, ShetA, ShamsundarR, EkstrandML. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1subtype C: Evidence of etravirine cross-resistance. AIDS, 2011; 25:1123–1126.
7.
VargheseV, ShahriarR, RheeSYet al.Minority variants associated with transmitted and acquired HIV-1 non-nucleoside reverse transcriptase inhibitor resistance: Implications for the use of second-generation non-nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr, 2009; 52:309–315.
8.
RuxrungthamK, PedroRJ, LatiffGHet al.Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, non-nucleoside reverse transcriptase inhibitor-experienced patients: Study TMC125-C227. HIV Med, 2008; 9:883–896.
